Trump is backing psychedelic research: here’s why

Last month President Trump signed an executive order designed to fast track both research and access to psychedelic drugs as treatments for mental health illnesses. The most prominent in the order was ibogaine, a drug derived from the root bark of a West African shrub, that has shown some promise in relieving the long term effects of traumatic brain injury. Madeleine Finlay talks to journalist Mattha Busby about podcaster Joe Rogan’s role in the story, what else is behind the President’s interest in psychedelic research, and what the order will change in practice for scientists and researchers. Help support our independent journalism at theguardian.com/sciencepod